Terns Pharmaceuticals (TERN) PT Raised to $36 at Barclays
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/2/2026
- Wall St rises as oil falls heading into US midterm elections
- Marvell agrees $115 billion all-stock deal to buy Lumentum
- Oil drops 7% as Iran signals openness to peace talks
- Why has the market become so unforgiving of AI earnings?
- EchoStar rises on report SpaceX in talks to buy Boost Mobile or tap its network
Tweet
Share
E-mailGet Alerts TERN Hot Sheet
Price: $52.95 --0%
Rating Summary:
4 Buy, 11 Hold, 0 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 20 | Down: 24 | New: 16
Rating Summary:
4 Buy, 11 Hold, 0 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 20 | Down: 24 | New: 16
Join SI Premium – FREE
Barclays analyst Etzer Darout raised the price target on Terns Pharmaceuticals (NASDAQ: TERN) to $36.00 (from $28.00) while maintaining a Overweight rating.
You May Also Be Interested In
- Bright Minds Biosciences Inc. (DRUG) PT Lowered to $107 at Baird amid partial clinical hold
- Scorpio Tankers (STNG) PT Raised to $105 at Evercore ISI
- Marvell (MRVL) PT Lowered to $275 at B.Riley
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
